Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy

Craig M. McDonald, Thomas Meier, Thomas Voit, Ulrike Schara, Chiara S M Straathof, M. Grazia D'Angelo, Günther Bernert, Jean Marie Cuisset, Richard S. Finkel, Nathalie Goemans, Christian Rummey, Mika Leinonen, Paolo Spagnolo, Craig M McDonald

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In Duchenne muscular dystrophy (DMD), progressive loss of respiratory function leads to restrictive pulmonary disease and places patients at significant risk for severe respiratory complications. Of particular concerns are ineffective cough, secretion retention and recurrent respiratory tract infections. In a Phase 3 randomized controlled study (DMD Long-term Idebenone Study, DELOS) in DMD patients 10-18 years of age and not taking concomitant glucocorticoid steroids, idebenone (900 mg/day) reduced significantly the loss of respiratory function over a 1-year study period. In a post-hoc analysis of DELOS we found that more patients in the placebo group compared to the idebenone group experienced bronchopulmonary adverse events (BAEs): placebo: 17 of 33 patients, 28 events; idebenone: 6 of 31 patients, 7 events. The hazard ratios (HR) calculated "by patient" (HR 0.33, p = 0.0187) and for "all BAEs" (HR 0.28, p = 0.0026) indicated a clear idebenone treatment effect. The overall duration of BAEs was 222 days (placebo) vs. 82 days (idebenone). In addition, there was also a difference in the use of systemic antibiotics utilized for the treatment of BAEs. In the placebo group, 13 patients (39.4%) reported 17 episodes of antibiotic use compared to 7 patients (22.6%) reporting 8 episodes of antibiotic use in the idebenone group. Furthermore, patients in the placebo group used systemic antibiotics for longer (105 days) compared to patients in the idebenone group (65 days). This post-hoc analysis of DELOS indicates that the protective effect of idebenone on respiratory function is associated with a reduced risk of bronchopulmonary complications and a reduced need for systemic antibiotics.

Original languageEnglish (US)
JournalNeuromuscular Disorders
DOIs
StateAccepted/In press - Apr 5 2016

Fingerprint

Duchenne Muscular Dystrophy
Placebos
Anti-Bacterial Agents
idebenone
Cough
Respiratory Tract Infections
Glucocorticoids
Lung Diseases
Steroids

Keywords

  • Airway infection
  • Duchenne muscular dystrophy
  • Idebenone
  • Respiratory function

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)
  • Neurology
  • Clinical Neurology
  • Genetics(clinical)

Cite this

Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. / McDonald, Craig M.; Meier, Thomas; Voit, Thomas; Schara, Ulrike; Straathof, Chiara S M; D'Angelo, M. Grazia; Bernert, Günther; Cuisset, Jean Marie; Finkel, Richard S.; Goemans, Nathalie; Rummey, Christian; Leinonen, Mika; Spagnolo, Paolo; McDonald, Craig M.

In: Neuromuscular Disorders, 05.04.2016.

Research output: Contribution to journalArticle

McDonald, CM, Meier, T, Voit, T, Schara, U, Straathof, CSM, D'Angelo, MG, Bernert, G, Cuisset, JM, Finkel, RS, Goemans, N, Rummey, C, Leinonen, M, Spagnolo, P & McDonald, CM 2016, 'Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy', Neuromuscular Disorders. https://doi.org/10.1016/j.nmd.2016.05.008
McDonald, Craig M. ; Meier, Thomas ; Voit, Thomas ; Schara, Ulrike ; Straathof, Chiara S M ; D'Angelo, M. Grazia ; Bernert, Günther ; Cuisset, Jean Marie ; Finkel, Richard S. ; Goemans, Nathalie ; Rummey, Christian ; Leinonen, Mika ; Spagnolo, Paolo ; McDonald, Craig M. / Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. In: Neuromuscular Disorders. 2016.
@article{126d4c5b81f74a4b8289d8698f87743c,
title = "Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy",
abstract = "In Duchenne muscular dystrophy (DMD), progressive loss of respiratory function leads to restrictive pulmonary disease and places patients at significant risk for severe respiratory complications. Of particular concerns are ineffective cough, secretion retention and recurrent respiratory tract infections. In a Phase 3 randomized controlled study (DMD Long-term Idebenone Study, DELOS) in DMD patients 10-18 years of age and not taking concomitant glucocorticoid steroids, idebenone (900 mg/day) reduced significantly the loss of respiratory function over a 1-year study period. In a post-hoc analysis of DELOS we found that more patients in the placebo group compared to the idebenone group experienced bronchopulmonary adverse events (BAEs): placebo: 17 of 33 patients, 28 events; idebenone: 6 of 31 patients, 7 events. The hazard ratios (HR) calculated {"}by patient{"} (HR 0.33, p = 0.0187) and for {"}all BAEs{"} (HR 0.28, p = 0.0026) indicated a clear idebenone treatment effect. The overall duration of BAEs was 222 days (placebo) vs. 82 days (idebenone). In addition, there was also a difference in the use of systemic antibiotics utilized for the treatment of BAEs. In the placebo group, 13 patients (39.4{\%}) reported 17 episodes of antibiotic use compared to 7 patients (22.6{\%}) reporting 8 episodes of antibiotic use in the idebenone group. Furthermore, patients in the placebo group used systemic antibiotics for longer (105 days) compared to patients in the idebenone group (65 days). This post-hoc analysis of DELOS indicates that the protective effect of idebenone on respiratory function is associated with a reduced risk of bronchopulmonary complications and a reduced need for systemic antibiotics.",
keywords = "Airway infection, Duchenne muscular dystrophy, Idebenone, Respiratory function",
author = "McDonald, {Craig M.} and Thomas Meier and Thomas Voit and Ulrike Schara and Straathof, {Chiara S M} and D'Angelo, {M. Grazia} and G{\"u}nther Bernert and Cuisset, {Jean Marie} and Finkel, {Richard S.} and Nathalie Goemans and Christian Rummey and Mika Leinonen and Paolo Spagnolo and McDonald, {Craig M}",
year = "2016",
month = "4",
day = "5",
doi = "10.1016/j.nmd.2016.05.008",
language = "English (US)",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy

AU - McDonald, Craig M.

AU - Meier, Thomas

AU - Voit, Thomas

AU - Schara, Ulrike

AU - Straathof, Chiara S M

AU - D'Angelo, M. Grazia

AU - Bernert, Günther

AU - Cuisset, Jean Marie

AU - Finkel, Richard S.

AU - Goemans, Nathalie

AU - Rummey, Christian

AU - Leinonen, Mika

AU - Spagnolo, Paolo

AU - McDonald, Craig M

PY - 2016/4/5

Y1 - 2016/4/5

N2 - In Duchenne muscular dystrophy (DMD), progressive loss of respiratory function leads to restrictive pulmonary disease and places patients at significant risk for severe respiratory complications. Of particular concerns are ineffective cough, secretion retention and recurrent respiratory tract infections. In a Phase 3 randomized controlled study (DMD Long-term Idebenone Study, DELOS) in DMD patients 10-18 years of age and not taking concomitant glucocorticoid steroids, idebenone (900 mg/day) reduced significantly the loss of respiratory function over a 1-year study period. In a post-hoc analysis of DELOS we found that more patients in the placebo group compared to the idebenone group experienced bronchopulmonary adverse events (BAEs): placebo: 17 of 33 patients, 28 events; idebenone: 6 of 31 patients, 7 events. The hazard ratios (HR) calculated "by patient" (HR 0.33, p = 0.0187) and for "all BAEs" (HR 0.28, p = 0.0026) indicated a clear idebenone treatment effect. The overall duration of BAEs was 222 days (placebo) vs. 82 days (idebenone). In addition, there was also a difference in the use of systemic antibiotics utilized for the treatment of BAEs. In the placebo group, 13 patients (39.4%) reported 17 episodes of antibiotic use compared to 7 patients (22.6%) reporting 8 episodes of antibiotic use in the idebenone group. Furthermore, patients in the placebo group used systemic antibiotics for longer (105 days) compared to patients in the idebenone group (65 days). This post-hoc analysis of DELOS indicates that the protective effect of idebenone on respiratory function is associated with a reduced risk of bronchopulmonary complications and a reduced need for systemic antibiotics.

AB - In Duchenne muscular dystrophy (DMD), progressive loss of respiratory function leads to restrictive pulmonary disease and places patients at significant risk for severe respiratory complications. Of particular concerns are ineffective cough, secretion retention and recurrent respiratory tract infections. In a Phase 3 randomized controlled study (DMD Long-term Idebenone Study, DELOS) in DMD patients 10-18 years of age and not taking concomitant glucocorticoid steroids, idebenone (900 mg/day) reduced significantly the loss of respiratory function over a 1-year study period. In a post-hoc analysis of DELOS we found that more patients in the placebo group compared to the idebenone group experienced bronchopulmonary adverse events (BAEs): placebo: 17 of 33 patients, 28 events; idebenone: 6 of 31 patients, 7 events. The hazard ratios (HR) calculated "by patient" (HR 0.33, p = 0.0187) and for "all BAEs" (HR 0.28, p = 0.0026) indicated a clear idebenone treatment effect. The overall duration of BAEs was 222 days (placebo) vs. 82 days (idebenone). In addition, there was also a difference in the use of systemic antibiotics utilized for the treatment of BAEs. In the placebo group, 13 patients (39.4%) reported 17 episodes of antibiotic use compared to 7 patients (22.6%) reporting 8 episodes of antibiotic use in the idebenone group. Furthermore, patients in the placebo group used systemic antibiotics for longer (105 days) compared to patients in the idebenone group (65 days). This post-hoc analysis of DELOS indicates that the protective effect of idebenone on respiratory function is associated with a reduced risk of bronchopulmonary complications and a reduced need for systemic antibiotics.

KW - Airway infection

KW - Duchenne muscular dystrophy

KW - Idebenone

KW - Respiratory function

UR - http://www.scopus.com/inward/record.url?scp=84969972170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969972170&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2016.05.008

DO - 10.1016/j.nmd.2016.05.008

M3 - Article

C2 - 27238057

AN - SCOPUS:84969972170

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

ER -